Biohaven, Ovid try to go public | Chemical & Engineering News
Volume 95 Issue 16 | p. 13 | Concentrates
Issue Date: April 17, 2017

Biohaven, Ovid try to go public

Department: Business
Keywords: biotechnology, Ovid, Biohaven, IPO

Two biotech companies developing compounds brought in from larger firms are attempting to go public. Biohaven Pharmaceutical aims to raise $100 million in an initial public offering. The funds will support Phase III studies of rimegepant, a migraine treatment licensed from Bristol-Myers Squibb, and earlier-stage studies of compounds for spinocerebellar ataxia and Rett syndrome. Meanwhile, Ovid Therapeutics hopes its IPO will bring in $86 million to fund R&D, including several studies of OV101, a rare-disease drug licensed from Lundbeck.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment